The Path Ahead: Medicines For Europe Head Highlights Opportunities And Risks
Examining The Future Landscape For Generics, Biosimilars And Value Added Medicines
In the third and final part of an exclusive three-part interview with Generics Bulletin, Medicines for Europe director general Adrian van den Hoven looks to the opportunities ahead for value added medicines and biosimilars in Europe, as well as the potential solutions to the pressures facing small-molecule generics.
